Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Cells|March 25, 2022
BTK Inhibitors Impair Platelet-Mediated Antifungal ActivityVincenzo Nasillo, Ivana Lagreca, Daniela Vallerini, et al.
Clinical Case Reports|December 17, 2016
All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with <i>NPM1</i>-mutated AML unfit for intensive chemotherapy and review of the literatureFabio Forghieri, Sara Bigliardi, Chiara Quadrelli, et al.
EMBO Molecular Medicine|October 20, 2020
Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumoniaLara Gibellini, Sara De Biasi, Annamaria Paolini, et al.
Blood|September 21, 2011
Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patientsLeonardo Potenza, Daniela Vallerini, Patrizia Barozzi, et al.
Medical Mycology|December 27, 2015
The bone marrow represents an enrichment site of specific T lymphocytes against filamentous fungiDaniela Vallerini, Giovanni Riva, Patrizia Barozzi, et al.
Transplantation|March 24, 2017
Multicenter Prospective Study for Laboratory Diagnosis of HHV8 Infection in Solid Organ Donors and Transplant Recipients and Evaluation of the Clinical Impact After TransplantationAngela Chiereghin, Patrizia Barozzi, Evangelia Petrisli, et al.
International Journal of Molecular Sciences|March 6, 2021
Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel ImmunotherapiesVincenzo Nasillo, Giovanni Riva, Ambra Paolini, et al.
International Journal of Molecular Sciences|September 10, 2021
Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid LeukemiaFabio Forghieri, Giovanni Riva, Ivana Lagreca, et al.
Blood|December 9, 2016
BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitorsPatrizia Comoli, Sabrina Basso, Giovanni Riva, et al.
Oncotarget|November 18, 2015
Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signalingLaura Mediani, Federica Gibellini, Jessika Bertacchini, et al.
Pageof 5